Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 58.8% in June

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 92,000 shares, a drop of 58.8% from the May 31st total of 223,200 shares. Based on an average trading volume of 1,476,400 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Up 1.0 %

OTCMKTS:BAYRY traded up $0.07 during mid-day trading on Friday, hitting $7.04. The company had a trading volume of 707,797 shares, compared to its average volume of 748,317. The business has a fifty day simple moving average of $7.48 and a 200-day simple moving average of $7.87. The company has a current ratio of 1.31, a quick ratio of 0.87 and a debt-to-equity ratio of 1.06. Bayer Aktiengesellschaft has a 1 year low of $6.89 and a 1 year high of $14.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Tuesday, May 14th. The company reported $0.77 earnings per share (EPS) for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 17.57% and a negative net margin of 6.70%. The business had revenue of $14.95 billion for the quarter. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.

Bayer Aktiengesellschaft Cuts Dividend

The firm also recently announced a dividend, which was paid on Monday, May 13th. Stockholders of record on Tuesday, April 30th were given a dividend of $0.0191 per share. The ex-dividend date was Monday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -2.30%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BAYRY. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, March 7th. The Goldman Sachs Group started coverage on Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.